Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- High Court’s Ruling in Iressa Appeal “Extremely Fair and Reasonable”: Attorney for AZ
November 16, 2011
- Survey Finds 33% Pharmacists and Pharmacy Students Know “Established Drugs”
November 16, 2011
- Anticancer Drug SyB L-0501 Starts PII Trial for Refractory, Relapsed Multiple Myeloma (MM): SymBio
November 16, 2011
- MEDINET Initiates Clinical Study of DC Vaccine
November 16, 2011
- Japan’s Jul-Sep 2011 Ethical Drug Market Grows 7.7%: IMS Japan
November 15, 2011
- Domestic Vaccine Market Showing Strong Growth
November 15, 2011
- Sawai President to Increase “Hospital MRs” to 100
November 15, 2011
- CMIC to Develop Orphan Drugs With Partners, Funds: Chairman Nakamura
November 15, 2011
- Bayer Yakuhin Modifies Storage Conditions for Kogenate FS for Home Use
November 15, 2011
- EPS: Solid Growth in Sales, Profits Driven by SMO, CSO Businesses
November 15, 2011
- Otsuka Draws Up Strategy in Anticipation of Abilify Patent Expiration
November 14, 2011
- Otsuka Forms Alliance with Lundbeck in CNS Field
November 14, 2011
- Astellas Completes Recombinant Flu Vaccine Inoculation of Subjects of PII Trials
November 14, 2011
- SymBio Initiates Domestic PII Clinical Trials of Bendamustine for Add’l Indications
November 14, 2011
- Pharmaceutical Sales Down 2.2 % due to Decrease in Sales of Elplat: Yakult
November 14, 2011
- Antibody Drugs to Support Kyowa Kirin’s Growth Over Next 10 Years: Dr Oshima
November 14, 2011
- Sawai’s Sales Up 4.3%, Showed Sluggish Growth Due to Break in Positive Impact of 2010 Premium Revision
November 14, 2011
- Favorable Results from PII Trial of Ono’s Ca Receptor Agonist Announced in US
November 14, 2011
- Rohto: Sales, Profits Driven By Growth in Asian Market
November 14, 2011
- Meiji HD: Pharmaceutical Sales Up 1% in Apr-Sep on Reflex Growth
November 11, 2011
ページ
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Recent trends are creating a fascinating push-and-pull effect in the talent market. We’re seeing more positions opening up, but also a greater number of candidates available, particularly in the fields of rare diseases and oncology. This “more positions, more candidates”…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…